Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein Vaccine

BACKGROUND: COVID-19 vaccines with alternative strain compositions are needed to provide broad protection against newly emergent SARS-CoV-2 variants of concern. METHODS: We conducted a global Phase 3, multi-stage efficacy study (NCT04904549) among adults aged ≥18 years. Participants were randomized...

Descripción completa

Detalles Bibliográficos
Autores principales: Dayan, Gustavo H., Rouphael, Nadine, Walsh, Stephen R., Chen, Aiying, Grunenberg, Nicole, Allen, Mary, Antony, Johannes, Asante, Kwaku Poku, Bhate, Amit Suresh, Beresnev, Tatiana, Bonaparte, Matthew I, Ceregido, Maria Angeles, Dobrianskyi, Dmytro, Fu, Bo, Grillet, Marie-Helene, Keshtkar-Jahromi, Maryam, Juraska, Michal, Kee, Jia Jin, Kibuuka, Hannah, Koutsoukos, Marguerite, Masotti, Roger, Michael, Nelson L., Reynales, Humberto, Robb, Merlin L., Villagómez Martínez, Sandra M., Sawe, Fredrick, Schuerman, Lode, Tong, Tina, Treanor, John, Wartel, T. Anh, Diazgranados, Carlos A., Chicz, Roman M., Gurunathan, Sanjay, Savarino, Stephen, Sridhar, Saranya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9753788/
https://www.ncbi.nlm.nih.gov/pubmed/36523415
http://dx.doi.org/10.1101/2022.12.05.22282933

Ejemplares similares

Ejemplares similares